Literature DB >> 28538630

The evolution of care improves outcome in blunt thoracic aortic injury: A Western Trauma Association multicenter study.

Steven R Shackford1, Casey E Dunne, Riyad Karmy-Jones, William Long, Desarom Teso, Martin A Schreiber, Justin Watson, Cheri Watson, Robert C McIntyre, Lisa Ferrigno, Mark L Shapiro, Kevin Southerland, Julie A Dunn, Paul Reckard, Thomas M Scalea, Megan Brenner, William A Teeter.   

Abstract

BACKGROUND: The management of blunt thoracic aortic injury (BTAI) has evolved radically in the last decade with changes in the processes of care and the introduction of thoracic endovascular aortic repair (TEVAR). These changes have wrought improved outcome, but the direct effect of TEVAR on outcome remains in question as previous studies have lacked vigorous risk adjustment and long-term follow-up. To address these knowledge gaps, we compared the outcomes of TEVAR, open surgical repair, and nonoperative management for BTAI.
METHODS: Eight verified trauma centers recruited from the Western Trauma Association Multicenter Study Group retrospectively studied all patients with BTAI admitted between January 1, 2006, and June 30, 2016. Data included demographics, comorbidities, admitting physiology, injury severity, in-hospital care, and outcome.
RESULTS: We studied 316 patients with BTAI; 57 (18.0%) were in extremis and died before treatment. Of the 259 treated surgically, TEVAR was performed in 176 (68.0%), open in 28 (10.8%), hybrid in 4 (1.5%), and nonoperative in 51 (19.7%). Thoracic endovascular aortic repair and open repair groups had similar Injury Severity Scale score, chest Abbreviated Injury Scale score, Trauma and Injury Severity Score, and probability of survival, but differed in median age (open: 28 [interquartile range {IQR}, 19-51]; TEVAR: 46 [IQR, 28-60]; p < 0.007), zone of aortic injury (p < 0.001), and grade of aortic injury (open: 6 [IQR, 4-6]; TEVAR: 2 [IQR, 2-4]; p < 0.001). The overall in-hospital mortality was 6.6% (TEVAR: 5.7%, open: 10.7%, nonoperative: 3.9%; p = 0.535). Of the 240 patients who survived to discharge, two died (one at 9 months and one at 8 years); both were managed with TEVAR, but the deaths were unrelated to the aortic procedure. Stent graft surveillance computed tomography scans were not obtained in 37.6%.
CONCLUSIONS: The mortality of BTAI continues to decrease. Thoracic endovascular aortic repair, when anatomically suitable, should be the treatment of choice. Open repair remains necessary for more proximal injuries. Process improvement in computed tomography imaging in follow-up of TEVAR is warranted. LEVEL OF EVIDENCE: Therapeutic/care management, level III.

Entities:  

Mesh:

Year:  2017        PMID: 28538630     DOI: 10.1097/TA.0000000000001555

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  4 in total

1.  Delayed endovascular aortic repair is associated with reduced in-hospital mortality in patients with blunt thoracic aortic injury.

Authors:  Christina L Marcaccio; Ryan P Dumas; Yanlan Huang; Wei Yang; Grace J Wang; Daniel N Holena
Journal:  J Vasc Surg       Date:  2018-02-13       Impact factor: 4.268

2.  Thoracic endovascular repair (TEVAR) versus open surgery for blunt traumatic thoracic aortic injury.

Authors:  Dominic Pang; Diane Hildebrand; Paul Bachoo
Journal:  Cochrane Database Syst Rev       Date:  2019-02-06

3.  Longer-term rates of survival and reintervention after thoracic endovascular aortic repair (TEVAR) for blunt aortic injury: a retrospective population-based cohort study from Ontario, Canada.

Authors:  Christopher C D Evans; Wenbin Li; Michael Yacob; Susan Brogly
Journal:  Trauma Surg Acute Care Open       Date:  2022-03-24

4.  The Role of Surgical and Endovascular Repair of Blunt Traumatic Aortic Injury in the Modern Era: A Single-Center Experience.

Authors:  Hamed Ghoddusi Johari; Seyed Arman Moein; Ahmad Hosseinzadeh; Javad Kojuri; Amirhossein Roshanshad; Reza Shahriarirad
Journal:  Bull Emerg Trauma       Date:  2022-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.